NetworkNewsBreaks – Altimmune Inc. (NASDAQ: ALT) Closes Public Offering Totaling $132.3 Million
Altimmune (NASDAQ: ALT), a clinical-stage biopharmaceutical company, has completed an underwritten public offering resulting in gross proceeds for the company of an estimated $132.2 million. According to a recent announcement, the company closed the offering of 4,119,564 shares of its common stock, including 750,000 additional shares pursuant to the full exercise of the over-allotment option granted to underwriters and other specific investors, prefunded warrants to purchase 1,630,436 shares of ALT common stock at an exercise price of $0.0001 per share. The public offering price of each share was $23, while the public offering price of each prefunded warrant was $22.999 per…







